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Antileukoprotease is known to be an antiproteolytic com-
pound of mu.co~s ~ecretions in hu~ans. ~hile s.earching for 
peptide-like mhlbltors of neutroplul-denved senne proteases 
in horny layers of human skin, we isolated a potent inhibitor 
of human leukocyte elastase (EC 3.4.21.37) and cathepsin G 
(EC 3.4.21.20) from psoriatic scales. This inhibitor showed 
inhibitory constants for human leukocyte elastase of approx-
imately 0.5-2 X 10-10 M and for cathepsin G of 2-4 X 
A ntiproteolytic pep tides and proteins are conside:ed. to be important regulators of tissue breakdown In in-flammatory diseases that are caused by serine proteases of neutrophils. Human leukocyte elastase (HLE) and cathepsin G (CG) are thought to cause or augment the 
proteolytic tissue damage in lung emphysema [1] ~nd. adult .resRira-
tory distress syndrome (ARDS) [2]. Because earher inveStigatIOns 
revealed elevated activities of these enzymes in psoriasis [3,4], an 
inflammatory skin disease where neutrophils infiltrate the epider-
mis, detailed knowledge about inhibitors present in skin appears to 
be essential. Up to now, only three compounds with antiproteolytic 
activity have been demonstrated in skin: the serum-derived proteins 
lXI-proteinase inhib.it?r [5], lX2:macroglobulin [6],. and. eiafin,. a.n 
elastase-specific inl1lbltory peptide [7]. Because peptlde-hke inhIbi-
tors are thought to be much more efficient than anti proteolytic 
proteins in regulating proteolytic tissue breakdown [8], we looked 
for the presence of further anti proteolytic peptides in horny layers 
of human skin. 
MATERIALS AND METHODS 
The horny layers from approximately 100 psoriatic patients were pooled for 
extraction a.nd purification to homogeneity of peptide-like inhibitors of 
human leukocyte elastase and cathepsin G. 
Extraction Eighty grams of psoriatic scales were suspended in 100-
200 ml distilled water, acidified to pH 2.B by addition of 1 % citrate and 
formic acid and diluted with 10% methanol (97%). After mechanical 
disruption by freeze-thawing (three times) as well as ultraturrax homogeni-
zation (10 min on ice) the solution was centrifuged (6000 X g, 10 min) . The 
supernatants were concentrated by membrane ultrafiltration (Amicon YM5; 
Amicon Corp., Danvers, MA) and cleared by membrane filtratIOn (5 ,urn). 
Buffer was changed to 0.01 M ammonium formate pH 4 by discontinuous 
membrane ultrafiltration (Amicon YM5) using three times the tenfold sam-
ple volume (diafiltration). 
Purification The first purification step consisted of a cation exchange 
TSK CM 3-SW HPLC (150 X 7.5 mm; LKB, Bromma, Sweden). The 
extract (6 ml) was divided into two portions that were cromatographed 
separately. Proteins were eluted with a 30-mllinear gradient (flow, 1 mil 
min) from 0.01 M-0.5 M ammonium formate at pH 4 and finally with 
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1O-~ N. The N-terminal amino acid sequence of the purified 
peptide matched the sequence of antileukoprotease and both 
peptides showed the same Mr on SDS-PAGE. Therefore, 
a.n~il.eu~oprotease may n<;>t only regulate serine protease ac-
tivities m mucous secretions, but also in skin. Key words: 
antileukoprotease/human leukocyte elastase/cathepsin G. 
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20 m! 0.5 M ammonium formate pH 3. Fractions of both runs showing 
mhlbltory activity agamst HLE and CG were combined concentrated and 
diafiltered (Amicon YM5) against 0.1 % trifluoroacetic ~cid (TFA). ' 
. It~hibitors were further purified by reverse-phase Cs high-performance 
hqUid chromatography (HPLC) (Nucleosil 300-7 CB, 250 mm X t inch; 
Macherey-Nagel, Duren, Germany), elution buffer A 0.1 % TFA in water, 
B 0.1% TFA in acetonitrile, eluting (flow, 3 mljrnin) with 15 ml 20% B, 
followed by a 75-mllinear gradient of from 20% to 60% B and final elution 
with 100% B. 
Relevant fractions were pooled, lyophilized, and further purified by re-
verse-phase CwHPLC (Nucleosil 300-7 C1B, 250 mm X t inch; Ma-
cherey-Nagel), elution buffer A 0.1 % TFA in water, B 0.1 % TFA in acetoni-
trile, e1uti~g (flow, 2 ml/min) with 10 ml 20% B, followed by a 50-ml 
Imear gradient of from 20% to 60% B and final elution with 100% B. 
Relevant fractions were pooled and further purified on a cyanopropyl-
column (250 X 4.6 mm, Baker, Phillipsburg, NJ), elution buffer A 0.1 % 
TFA m water, bu~er B 100% n-propanol, using a gradient from 10-35% 
buffer B over 25 mm (flow, 1 mljmin) with subsequent elution with 100% 
buffer B. 
The relevant fractions were finally purified on an analytical reverse-phase 
Cis-HPLC column (Nucleosil 100-5 CIB, 250 X 4.6 mm; Bischoff, Leon-
berg, Germany), elution buffer A 0.1 % TFA in water, buffer B 0.1 % TFA in 
acetonitrile , eluting with a 30-ml linear gradient (flow, 1 mljmin) from 
10% to 40% buffer B. 
Inhibito.ry Acti,:ity Inhibi~ion of HLE and CG was determined by the 
hydrolysIs of speCific tetrapeptide substrates according to Nakaj ima et al (9). 
For HLE we used the substrate methox),succinyl-alanyl-alanyl-prolyl-
valine-p-nitroanilide (Meo-Suc-Ala-Ala-Pro-Val-NA; Sigma, Deisenhofen, 
Germany), for CG the substrate succinyl-alanyl-alanyl-prolyl-phenylala-
nine-p-nitroanilide (Suc-Ala-.Ala-Pr?-Phe-NA; Sigma). Inhibitory activity 
was measured by 30~m1l1 pre1l1cu.batlon of 20 ng of either enzyme (Elastin 
Products Corp., Pacific, MO) With 1-10,u1 test sample in 200,ul 0.1 M 
~EPES, 0.5 M NaCI, 10% Me2SO, pH 7.5 before adding 0.5 mM substrate 
111 BOO ,ul of the same buffer. The absorbance at 405 nm was measured using 
an Eppendorf spectrophotometer. 
For determination of K; all solutions contained 1 % bovine serum albumin 
(RIA grade; Sigma) and final substrate concentrations were 2 mM. HLE 
activity was active-site titrated with recombinant elalin. Titration with 
active-site-titrated HLE revealed the inhibitor to be more than 90% active. 
The apparent K; was determined graphically according to the method of 
Green and Work [10.1 and the K; was determined by a graphical method that 
compares data With sunulated plots for tight binding inhibition with various 
K; using Henderson's equation 13 [11) : 
_I_, _= E, + K. (A, + K.) 5. 
1-~ I KjJ Vi' 
1'. 
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with I" total concentration of inhibitor (0 -60 nM); II" velocity in the 
presence of inhibitor; v" velocity without inhibitor; E" tota l concentration 
of enzyme (HLE 20 nM, CG 20 nM); K; , dissociation constant for inhibitor; 
A" tota l concentration of substrate (2 mM); K. , Michaelis constant for 
substrate (Meo-Suc-Ala-Ala-Pro-Val-NA, 0.14 rnM; Suc-Ala-Ala-Pro-Phe-
NA, 2.9 mM) . 
The equation was rearranged to 
.!i = (K,(E, - 1, - K,) - A,1<, 
If, 
+ JA:Kf + 2A,1<,K,(E, + 1, + K,) + K! [E: + 2E,(K, I,} + Po + 21,1<, + Kfj) /2K,E" 
to plot inhibition curves (v,fv, versus I, by means of standard software (Sigma 
plot 4. 1 or Microsoft Excel 4.0). I, was varied [0,1, .. . ,60] nM assuming a 
1 : 1 molar inhibition for HLE according to [12] . Inhibition curves for CG 
inhibition were based on the assumption of a 2: 1 CG-inhibitor stoichiome-
try [1 2]. Therefore, the functional normali ty of the inhibitor I, [0,2, .. . , 
120] nN was used for determination of K,. 
Size-Exclusion HPLC For determination of the apparent molecular 
mass, samples were chromatographed on a TSK 2000 SW column (600 X 
7.5 mm; LKB) equipped with a TSKSWP precolumn (75 X 7.5 mm) using 
0.1 % TFA at a fl ow of 1 ml/ min. UV absorption was recorded at 215 nm 
and fractions were collected automatically (20 drops/fraction). M, was cali-
brated with the peptides insulin B-chain fragment 22- 36, glucagon, elafin 
(prepared accord ing to [7]), aprotinin, ubiquitin, ribonuclease A, soybean 
trypsin inhibitor, ovomucoid trypsin inhibitor, and bovine senlln albumin 
(ca librators obtained from Sigma or Serva, Heidelberg, Germany). 
Sodiumdodecylsulfate-Polyacrylamide Gel-Electrophoresis (SDS-
PAGE) The apparent molecular weight was determined by SOS-PAGE 
according to the method of Schagger and von Jagow [B]under reducing 
conditions (dithiothreitol, 100 mg/ml; Sigma) and as markers we used 
myoglobulin fragments MW -SOS-17 (Sigma) with molecular weights in-
terpreted according to [1 4]. After fixation w ith 2% glutaraldehyde, poly-
peptides were stained using a silver staining kit (Si gma). For reference we 
used rec9mbinant an tileukoprotease kindly provided by Dr. Heinzel-
Wieland, Gri.inenthal GmbH, Aachen, Germany. 
Amino Acid Sequence Analysis The purified freeze-dried sample was 
solubilized in distilled water and an al iquot equivalent to 141lg was sub-
jected to N -terminal sequence analysis on an Applied Biosystems 477 pulsed 
liquid-phase sequencer with on-line analysis of the phenylthiohydantoins 
usin g a 120 A PTH ana lyzer. Gradients were used according to the recom-
mendations of the manufacturer. 
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Figure 1. Elastase inhibitory activity following cation-exchange HPLC of 
an acidic extract of 40 g psoriatic scales. Absorbance at 280 nm is shown by 
the solid line, inhibitory activity of fractions against human leukocyte elastase 
(HLE) by opetl bars, and against cathepsin G (CG) by hatched bars. 
RESULTS 
To prove the presence of peptide-like HLE inhibitors in psoriatic 
skin, we extracted 80 g of psoriatic scales, coll ected from appro>o.-i-
mately 100 patients, and subjected the extract to cation-exchange 
HPLC in two portions. Figure 1 shows a representative experiment, 
which indicates that at leas t two inhibitory species could be sepa-
rated by cation-exchange HPLC, one showing potent inhibitory 
activity against HLE (pool I) and a second showing inhibitory activ-
ity against HLE and CG (pool II). The relevant fractions (pool II) of 
both separations were combined and further purification was 
achieved by preparative reverse-phase C s HPLC (Fig 2A), which 
revealed a single peak of HLE and CG inhibitory activity. The 
inhibitory species was further purified on reverse-phase CIS HPLC 
(Fig 2B) . Active fractions were pooled and chromatographed on a 
cyanopropyl-HPLC (Fig 2C) . Final purification was achieved on an 
analytical reverse-phase CIS colum n (Fig 2D), which gave a single 
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Figure 2: Purification of active fractions from cation-exchange HPLC (corresponding to pool II) by preparative RP Ce HPLC (A) . Relevant fractions with 
HLE II1hlbltOry actiVity (hatclzed area) were combl11ed and further purified by preparative RP C
'S HPLC (B), cyanopropyl HPLC (C), and RP C HPLC (D). Solid litle, absorbance at 220 or 215 nlll; dotted litle, gradient used. 18 
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Figure 3. Inhibition of20 I~ h~ma~ leukocy~e e.lastas~ (HLE) a~d ~~ I:M 
cathepsin G (CG) by the pUrIfied mlubltor. SolId /r"es, simulated mhlbltIon 
curves for different Ki according to equation 13 of Henderson [ttl for 
reversible tight binding inhibitors. We assumed for HLE a 1 : 1 and for CG a 
2: 1 enzyme-inhibitor stoichiometry according to [12]. Therefore, Ki for 
HLE is given in molar concentration, the Ki for CG in functional normaliry. 
symmetrical A215 peak with inhibitory activity against HLE plus 
CG (Fig 3). 
A table of purification steps demonstrating protein content, in-
hibitory activity, and yield cannot be given, because at the begin-
ning the extract consists of a mixture of enzymes and several inhibi-
tors that make it impossible to evaluate the initial inhibitor 
concentration for each compound separately. Disregarding the 
presence of proteases, the total amount of extractable HLE inhibi-
tory activity was 2.56 flmol per 80 g psoriatic scales. From this, 32.5 
nmol anti leukoprotease could be completely purified. 
N-terminal amino acid sequence analysis of the first 37 residues 
revealed a partial sequence of antileukoprotease (Fig 4). Cysteine 
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Figure 4. N-terminal amino acid analysis of elastase inhibitory peptide 
from psoriatic scales aligned with the sequence of antileukoprotease <, 
obtained from [15 ,17]. Cysteins have not been determined. 
has not been determined, but aU positions in which no residue could 
be detected match a cysteine in the amino acid sequence known for 
antileukoprotease. By TSK 2000 size-exclusion HPLC of the puri-
fied inhibitor, an apparent molecular mass of 13-14 kD could be 
demonstrated (Fig 5) . The protein peak coeluted with the HLE-in-
hibitory activity (data not shown). In SDS-PAGE under reducing 
conditions (Fig. 6) the inhibitor showed a single band comigrating 
with recombinant antileukoprotease. Apparent molecular weight of 
antileukoprotease by SDS-P AGE was 14.7 kD, clearly overestimat-
ing the molecular mass of 11. 7 kD of recombinant antileukopro-
tease that had been calculated from the amino acid sequence [15] . 
The apparent inhibition constant according to the method of 
Green and Work [10] proved to be 9 X 10- 10 M for HLE and 3 X 
10-9 M for CG consistent with the apparent Ki for HLE determined 
by Thompson et af [15] . Ki was determined using Henderson's equa-
tion 13 [11] for simulation of inhibition curves for a tight binding 
reversible inhibitor. K. for the substrates (for HLE, Meo-Suc-Ala-
Ala-Pro-Val-NA; for CG, Suc-Ala-Ala-Pro-Phe-NA) was taken 
from [9] and found to be identical under our experimental condi-
tions. The Ki of antileukoprotease derived from psoriatic scales for 
HLE proved to be 0.5-2 X 10- 10 M, which is consistent with the 
Ki of 1.9 X 10- 10 determined by Smith and Johnson [16]. For CG 
inhibition, we found the Ki to be about 2-4 X 10-9 N, which is 
consistent with the Ki of 4 X 10-9 M known for antileukoprotease 
[16J and determined under the assumption of a 1 : 1 molar binding 
stoichiometry . 
DISCUSSION 
Antileukoprotease [17J is a very potent human serine protease, able 
to inhibit the neutrophil-derived serine proteases HLE and CG. 
This inhibitor is known to be present in a wide variety of human 
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Figure 5. Determination of the apparent molecular weight by TSK 2000 
SW size-exclusion HPLC. M, was calibrated with the peptides insulin 
B-chain fragment 22-36 (MW 1,086), glucagon (3,483), elafin (5,999), 
aprotinin (6,512), ubiquitin (8,451), ribonuclease A (13,700), soybean tryp-
sin inhibitor (22,000), ovomucoid trypsin inhibitor (27,000), and bovine 
serum albumin (67,000). Dotted Ii"e, elution time of antileukoprotease de-
rived from psoriatic scales. 
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Figure 6. SDS-PAGE of antileukoprotease derived from psoriatic scales 
(lane C) in comparison with recombinant antileukoprotease (lane B). As 
markers we used myoglobulin fragments (lanes A,D) with molecular 
weights given on the left margin. Polypeptides were stained by silver staining. 
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body fluids [18] such as bronchial mucus [19]' parotid secretions 
[20], seminal fluid [21], and cervical mucus [22]. The concept of a 
protease-anti protease imbalance, which is based on the assumption 
that tissue breakdown by excess HLE activity may be an important 
factor in the development oflung emphysema [23] and ARDS [24], 
has focussed attention on whether HLE inhibitors may regulate this 
process. The main HLE inhibitor of human serum, aI-proteinase 
inhibitor, could be shown to be much less effective in preventing 
hydrolys~s of tissue components than inhibitory active peptides like 
antileukoprotease or the medical leech-derived eglin C [8]. There-
fore , antileukoprotease is thought to playa major role in the physio-
logic regulation of HLE activity in the lungs. 
In human skin the concept of a protease-anti protease imbalance 
has been proposed by Dubertret et al [25], who found marked epi-
dermal proteolysis in psoriatic skin explants. At that stage the enzy-
matic activity could only be shown to be of serine protease type. 
There are three candidate serine proteases for the observed proteo-
lytic activity: HLE, CG, and proteinase 3. In earlier investigations 
we showed that HLE activity (and CG activity; unpublished) is 
present on the surface of psoriatic lesions [4], but not on uninvolved 
psoriatic skin and in healthy controls. Because HLE [26], CG, and 
proteinase 3 are present in azurophilic granules of neutrophils, they 
may represent a suitable source of HLE and CG in psoriatic epider-
mis. Furthermore, HLE activity has been demonstrated to be 
present on the surface of diseased skin in contact dermatitis and 
atopic dermatitis [4], but the cellular origin ofHLE activity in these 
skin diseases is not known. 
There have been only a few investigations concerning HLE 
inhibitors in human skin. Fraki and Hopsu [27] found that 
aI-proteinase inhibitor as well as az-macroglobulin, the HLE in-
hibitors of human serum, are present in human horny layers. Acid-
stable peptide-like inhibitors of HLE have been demonstrated in 
psoriatic epidermis [28,29]. Purification and detailed characteriza-
tion of these inhibitory activities revealed the presence of an elas-
tase-specific inhibitor, elafin [7], which has also recently been puri-
fied from bronchial mucus [30] . 
A second HLE inhibitor can be extracted from psoriatic scale 
material. We have developed a purification procedure using se-
quential HPLC to purify this inhibitor to homogeneity. The appar-
ent K j of the purified inhibitor for HLE and CG inhibition were 
comparable to those reported for antileukoprotease [16] derived 
from bronchial mucus. Amino acid sequence analysis (Fig 4) re-
vealed the N-terminal sequence of antileukoprotease [15,17], and 
the apparent molecular masses in SDS-PAGE of antileukoprotease 
derived from psoriatic scales and of recombinant human antileuko-
protease were identical (Fig 6). Therefore, the second HLE inhibi-
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tor derived from psoriatic scales seems to be identical with anti leu-
koprotease from mucous secretions in terms of N-terminal amino 
acid sequence, molecular size, and inhibitory properties. 
Approximately 400 nmol antileukoprotease/kg psoriatic scales 
can be completely purified from psoriatic scale material. Therefore, 
the concentration in the fluid phase of psoriatic scales is at least 
400 nM. The fact that the concentration of antileukoprotease ex-
ceeds the K j of 200 - 400 pM for HLE at least 1000 times indicates 
that antileukoprotease is present in psoriatic scales in physiologi-
cally relevant concentrations. 
The cellular origin of antileukoprotease in skin remains to be 
established. In human serum antileukoprotease serum level is 126 
jlg/ml [31], which is about 10 nM. Therefore, it seems unlikely that 
antileukoprotease is simply derived from serum contamination. 
Specific accumulation of serum-derived antileukoprotease seems to 
be possible. This is supported by the findings of Gast et al [32], who 
found approximately 15% of radio labeled antileukoprotease 5 min 
after being administered intravenously to rats in the skin. Another 
possible source that can be considered may be sweat glands. 
The presence of two potent peptide-like inhibitors of HLE in 
psoriatic scale material, antileukoprotease inhibiting HLE plus CG, 
as well as elafin-inhibiting HLE plus proteinase 3 [33], supports the 
hypothesis that at least in psoriasis the epidermis is protected against 
proteolytic degradation. Localized excess ofHLE, e.g., in the inter-
cellular space, however, might cause a protease-antiprotease imbal-
ance, leading to degradation of extracellular matrix components 
followed by the formation of spongiosis, bullae, blisters, or pustules, 
as seen in a variety of inflammatory skin disorders. 
Therefore, not only ARDS and lung emphysema, but also acute 
and chronic inflammatory skin disorders may profit from the devel-
opment of serine protease inhibitors for use in therapy. Some evi-
dence that reconstitution of the HLE-HLE inhibitor balance in pso-
riasis might be of therapeutic value is given by the fact that bathing 
in hypertonic salt solutions removes HLE from the surface of psori-
atic lesions [3,34]. Furthermore, it could be shown that tannin, 
which is used as an adjuvant in topical therapy of vesiculating skin 
disorders, is a potent irreversible in activator of HLE, but not of 
other closely related serine proteases [35] . In addition, preliminary 
data show that topical application of aI-proteinase inhibitor exerts 
beneficial therapeutic effects in the therapy of atopic dermatitis [36]. 
In conclusion, one of the most potent serine protease inhibitors in 
humans, antileukoprotease, is present in psoriatic scales in concen-
trations that are likely to be sufficient for inhibition of the neutro-
phil-derived serine proteases HLE and CG. The cellular origin of 
antileukoprotease in skin and the localization at the cellular level 
remain to be investigated. 
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ANNOUNCEMENT 
A symposium entitled "Melanin: Its Role in Human P?otoprotection" will be held at the Hyatt 
Regency Crystal City, W ashington. D.C. N ational Airport, U .S.A., March 11-12. 1994. The 
objective of the symposium is to review for the scientific, regulatory, ~usiness commun.ities and 
the general public at large the current knowledge of the role of melan111 111 UV protectIOn. The 
organizing committee is chaired by Dr. Miles R. Chedekel. Dr. Ago B. Ahene is the secretary. 
The registration desk will open at 3:00 p.m. on Thursday, March 10, 1994. and w ill be followed 
in the evening by a welcoming reception at the Hyatt Regency. The scientific sessions w ill 
begin at 9:00 a.m. on Friday, March 11. 1994. The conference Will end on Saturday, March 12, 
1994. 
The tentative program is divided into five plenary. sessions and will also include several 
Workshops and Round-table Discussions. The topics 111c1ude chemistry and physics of mela-
nins. melanin metabolism, natural distribution of melanins and photoprotection. absorptive and 
light-scattering properties of melanins and its precursors. melanin and free- radicals, and round-
table discussions. 
A second announcement and call for papers will be circulated this summer. For further 
information, please contact the Symposium Secretariat, Dr. Ago B. Ahene, Melani n Sympo-
sium Secretariat. 3696 Haven Avenue. Redwood City. California. 94063. U.S.A. Telephone. 
(415) 366-2626; Facsimile, (415) 368-4470. 
